Due to the clinical impact of the differential diagnosis between indolent (as CM) and aggressive forms of mastocytosis, this retrospective study proposes to evaluate the presence of CD30 immunomarker in a series of MCs lesions. This evidence concerns the gene TNFRSF8 and cutaneous mastocytosis.